Pituitary enlargement following ipilimumab without long term endocrine dysfunction

Ipilimumab, a monoclonal antibody against CTLA-4, is used in the treatment of melanoma and renal cell cancer. Hypophysitis is one of the more common adverse events, usually presenting with headache, pituitary enlargement and hypopituitarism, mostly ACTH deficiency, which is usually permanent. We des...

Full description

Saved in:
Bibliographic Details
Published in:Current problems in cancer 2021-12, Vol.45 (6), p.100710-100710, Article 100710
Main Authors: Nogueira, Edson, Menon, Arjun, Dede, Anastasia, Mitra, Indu, Brock, Cathryn, Larkin, James, Morganstein, Daniel
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - adverse effects
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Female
Glucocorticoids - therapeutic use
Humans
Hypophysitis
Hypophysitis - chemically induced
Hypophysitis - drug therapy
Hypopituitarism
Ipilimumab
Ipilimumab - adverse effects
Ipilimumab - therapeutic use
Male
Melanoma
Melanoma - diagnostic imaging
Melanoma - drug therapy
Middle Aged
Pituitary Diseases - chemically induced
Prednisolone - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ipilimumab, a monoclonal antibody against CTLA-4, is used in the treatment of melanoma and renal cell cancer. Hypophysitis is one of the more common adverse events, usually presenting with headache, pituitary enlargement and hypopituitarism, mostly ACTH deficiency, which is usually permanent. We describe a series of 3 cases developing pituitary enlargement in keeping with hypophysitis after ipilimumab without any long-term pituitary hormone deficiencies. This illustrates that a comprehensive endocrine assessment is required even when pituitary enlargement is present.
ISSN:0147-0272
1535-6345
DOI:10.1016/j.currproblcancer.2021.100710